Zimmer Biomet beats Q1 profit estimates; hikes FY earnings view

Zimmer Biomet Holdings

28/04/2026 11:38

Overview

U.S. medical device maker's Q1 net sales rose 9.3%, slightly beating analyst expectations

Adjusted EPS for Q1 rose 15.5%, beating analyst expectations

Company completed $250 mln in share repurchases during the quarter

Outlook

Zimmer Biomet raises 2026 adjusted diluted EPS guidance to $8.40-$8.55 from $8.30-$8.45

Company maintains 2026 reported revenue growth outlook at 2.5%-4.5%

Zimmer Biomet lifts 2026 free cash flow expectations

Result Drivers

NEW PRODUCT LAUNCHES - Co said continued momentum from recently launched products contributed to Q1 results

S.E.T. AND TECHNOLOGY SEGMENTS - Strongest sales growth came from Sports Medicine, Extremities, Trauma and Technology & Data, Bone Cement and Surgical product categories

DISCIPLINED EXECUTION - Co cited disciplined execution across the business as supporting Q1 performance, per CEO Ivan Tornos

Company press release: ID:nPn5w1CmZa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Slight Beat*
$2.09 bln
$2.07 bln (25 Analysts)
Q1 Adjusted EPS
Beat
$2.09
$1.86 (25 Analysts)
Q1 EPS
$1.22
Q1 Net Income
$238.10 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 20 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Zimmer Biomet Holdings, Inc is $100.00, about 8% above its April 27 closing price of $92.59

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)